Abstract 17P
Background
Breast Cancer is the most common yet preventable & treatable forms of cancer in the Philippines, hence a need to prioritize & strengthen organized screening programs to detect early & bridge to treatment to increase survival. The ACT Now PRIME CARE for Breast Cancer aims to detect breast cancer thru screening using integrated patient online education & self-evaluation with mobile clinic clinical breast exam, ultrasound, navigation to referral pathways for Centers with Medical Access Programs.
Methods
Women ages 40-60, were advised to register at actnow.philcancer.org.ph to access videos on breast health, cancer & self-exam. Patients' self-reported signs, symptoms & risk factors were triaged into high risk & low risk. Immediate scheduling of high-risk individuals to mobile clinic visit were done while low-risk individuals were advised to visit on a yearly basis. Patient education, Clinical Breast Exam & Ultrasound were performed. Both high risk & low risk groups were scheduled for teleconsultation or clinic visits. Suspicious breast findings were referred for immediate biopsy. Confirmed malignancy were referred to centers with medical access programs.
Results
Among women who completed the educational videos, 87% were evaluated to have good comprehension of the materials. Among 1,790 women screened, 277 were clinically high-risk patients & only 6 had breast ultrasound BIRADS 4-5. Two had negative biopsy results. Four had pending biopsy results. Two had confirmed positive early breast malignancy who were subsequently referred treatment. Turnaround time from work-up to treatment was 4 weeks. Among 1513 low risk women, majority have commitments to visit for screening once a year.
Conclusions
In a limited resource country, there's a need to strengthen community-based cancer screening, strengthen patient navigation & improve patients' awareness on available financial & medical access programs to improve compliance & survival. The ACT Now PRIME CARE is a pilot program to enhance education about breast health & cancer, capture cases in the community & provide immediate referral pathways to improve outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Philippine Cancer Society.
Funding
Philippine Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract